Telmisartan in High Cardiovascular Risk Patients

Cardiovascular disease (CVD) remains the leading global cause of morbidity and mortality, largely driven by hypertension and other risk factors. While ACE inhibitors are established as standard therapy, angiotensin receptor blockers (ARBs) provide effective alternatives. Among them, telmisartan is notable for its sustained 24-hour blood pressure control and additional cardiovascular protection. Results from the ONTARGET and TRANSCEND trials demonstrated that telmisartan reduces cardiovascular events as effectively as ramipril, but with superior tolerability. Current guidelines now endorse telmisartan as a key option to lower cardiovascular risk and morbidity. A review in European Cardiology underscores these findings, highlighting CVD management guidelines alongside pivotal clinical trial evidence and real-world data supporting telmisartan’s role.